anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Pediatric patients (2-21 y) diagnosed with IBD, IBS, or other gastrointestinal disorders. Fecal calprotectin Level.
AZD4635 capsule formulation 50 mg QD or 75 mg QD plus durvalumab and oleclumab. The pharmacokinetics of AZD4635 capsule formulation will be characterized on Cycle 1, 2, and 4 (Day 1) in Arm CB. Steady-state pharmacokinetics will be assessed on Cycle 2 Day 15. Cycle 1 will be administered in a 3-week cycle to assess the safety and dose-limiting toxicity (DLT). PKs will also be collected on Day 1 of Cycles 3 and 5.
Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker. Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients \< 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients \< 40 kg) to be taken for 24 months.
Two or more electrophysiology characteristics can be graphically represented in a single representation output, for example, by an electroanatomical mapping system. The system can generate or receive multiple electrophysiology maps, one for each of a corresponding number of electrophysiological characteristics. The system can also generate or receive a three-dimensional anatomical model, such as a cardiac surface model, that includes a focal point. The system can identify a display region about the focal point and transform the display region from a three-dimensional surface into a plane. One or more of the electrophysiology maps can be represented by varying the elevation of the plane, e.g., according to value(s) of the represented electrophysiological characteristic(s). One or more additional electrophysiology maps can be represented on the elevation-varied plane, e.g., in color scale, grey scale, or the like.
FIELD: in medicine for the treatment of cardiovascular diseases. SUBSTANCE: Reagent 1: forscoline, Reagent 2: acetone. Reaction conditions: in the presence of HCl. Reagent 3: a 1,9-isopropylidene derivative of forscoline. Reagent 4: alkali in alcohol. Reagent 5: a 7-diacetyl derivative or 1,9-isopropylidene derivative of forscoline. Reagent 6: beta-halopropionylhedine. Reaction conditions: in the presence of an organic base treatment of the resulting compound with alkali and deprotection at the 1,9-position of the resulting (3-substituted amino)propionyloxy derivative of forscoline and isolation of the desised product in the free state or as a pharmaceutically acceptable salt and optionally conversion into a 7-acetoxyderivative. The stage of reaction with an amine as well as a stage of reaction with an amine and a deprolection stage may be carried out in any sequence. The first and second stages as well as the fifth and sixth stages may be accomplished in a single stage. EFFECT: more efficient preparation process. 2 cl
Traditional skin sampling methods include punch or shave biopsies to produce a solid tissue sample for analysis. These biopsy procedures are painful, require anesthesia, and leave permanent scars. This unit describes a suction blister skin biopsy method that can be used in place of traditional biopsy methodologies as a minimally invasive, non-scarring skin sampling technique. The induction of suction blisters uses an instrument with a chamber that applies negative pressure and gentle heat to the skin. Blister formation occurs within 1 hr, producing up to five blisters, each 10 mm in diameter per biopsy site. Blister fluid can be extracted and centrifuged to retrieve cells from the epidermis and upper dermis for flow cytometry, single-cell RNA sequencing, cell culture, and more without the need for digestion protocols. In addition, the blister fluid can be used to measure soluble proteins and metabolites. This unit describes the preparation of supplies and subjects, the suction blister biopsy procedure and blister formation, fluid extraction, and post-blistering care. © 2024 Wiley Periodicals LLC. Basic Protocol 1: Preparation of supplies and subject Basic Protocol 2: Suction blister biopsy procedure and formation Basic Protocol 3: Blister fluid extraction Basic Protocol 4: Post-blister care and clean up.
PURPOSE: A small micro-vehicle which is derived from nucleated cells is provided to specifically treat and/or diagnose cancer tissue, blood vessel or inflammatory tissue. CONSTITUTION: A composition is derived from mammalian nucleated cells and contains micro-vehicles which are smaller than a cell. The nucleated cells are monocytes, macrophages, dendritic cells or stem cells. The nucleated cells are induced to specific cells or tissues. The micro-vehicle is prepared by sonication, cytolysis, homogenization, freezing-thawing, electroporation, mechanical lysis or chemical treatment of suspension containing the nucleated cells. A pharmaceutical composition is derived from the nucleated cells and contains shedding micro-vehicle in which material for treating or diagnosing disease is loaded. The material is anti-cancer agent, anti-inflammatory agent, peptide, protein, bead, microparticle, or nanoparticle.
BACKGROUND: Mosaic loss of Y chromosome (LOY) is the most common chromosomal alteration in aging men. Here, we use single-cell RNA and ATAC sequencing to show that LOY is present in the kidney and increases with age and chronic kidney disease.
RESULTS: The likelihood of a cell having LOY varies depending on its location in the nephron. Cortical epithelial cell types have a greater proportion of LOY than medullary or glomerular cell types, which may reflect their proliferative history. Proximal tubule cells are the most abundant cell type in the cortex and are susceptible to hypoxic injury. A subset of these cells acquires a pro-inflammatory transcription and chromatin accessibility profile associated with expression of HAVCR1, VCAM1, and PROM1. These injured epithelial cells have the greatest proportion of LOY and their presence predicts future kidney function decline. Moreover, proximal tubule cells with LOY are more likely to harbor additional large chromosomal gains and express pro-survival pathways. Spatial transcriptomics localizes injured proximal tubule cells to a pro-fibrotic microenvironment where they adopt a secretory phenotype and likely communicate with infiltrating immune cells.
CONCLUSIONS: We hypothesize that LOY is an indicator of increased DNA damage and potential marker of cellular senescence that can be applied to single-cell datasets in other tissues.
The disclosure discloses a remote exercise rehabilitation management system for people with chronic diseases, including a server terminal, a doctor terminal and a patient terminal. Multi-disease integration principles are built in the server. Multiple independent fitness assessment protocol and multiple exercise rehabilitation prescriptions suitable for patients with different chronic diseases are stored in the server. The patient terminal collects the patient information by a health and lifestyle questionnaire, and transmits the patient information to the server. The server will design a fitness assessment protocol according to the patient's health information, and sends the fitness assessment protocol to the patient terminal. The patient terminal is able to present the fitness assessment protocol and collect patient's feedback. According to the feedback and built-in principles, the server will design an exercise prescription suitable to patient's health conditions.
It has now been discovered that a high therapeutic effect in treating various disorders associated with enhanced activity of kinase p38 may be achieved by using a potent p38? kinase inhibitor compound which also has inhibitory activity against p38?. Furthermore, reducing the activities of both kinase p38? and kinase p38? without reducing the activity of a kinase p38? to such an extent that undesired side effects are observed upon administration to a subject having a disorder associated with enhanced activity of kinase p38 has been discovered to be achievable by modifying inhibitors of p38? such that the modification engenders inhibitory activity against p38?. Described are compounds with activity against p38? and p38?. Disclosed are methods of using described compounds and compositions to modulate a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits inhibition of the p38? and p38? MAPKs. Also disclosed are methods for identifying compounds which inhibit p38? and p38? MAPKs and which can modulate a stress activated protein kinase (SAPK) system.
The present invention relates to a medicine for treating hepatitis B. The tablet has the ingredients of the effective ingredients such as phyllanthus urinaria L and dextrin: starch with the proportion of 8 to 10:4:1. An alcohol extracting substance of which the effective ingredient is phyllanthus urinaria L whole herb and a residual substance after alcohol extraction are treated by water extraction; the alcohol extracting substance and the water extracting substance are mixed to be a mixture according to 1:1.2 to 1.4. The medicine for treating hepatitis B has convenient administration. Clinic experiments prove that the treating effects on the hepatitis B, the icterus liver and the fatty liver are good. The present invention can be used for treating various diseases of immune hypofunction.
In the 1960s, through laboratory-based investigations of peripheral blood partnered with detailed clinical annotations, Dr. Waldenström described a condition he called "benign monoclonal gammopathy". These patients were asymptomatic with a detectable monoclonal protein, and did not meet imaging and laboratory criteria for multiple myeloma. In 1978, through observational retrospective review of medical records, Dr. Kyle observed that not all cases of monoclonal gammopathy were benign. He introduced the term monoclonal gammopathy of undetermined significance (MGUS) to describe a condition that may potentially progress to multiple myeloma (MM), highlighting clinical inability in predicting which patients might progress. In 1980, Drs. Kyle and Greipp described 6 cases which did not fit the definitions of MGUS or MM, and they remained asymptomatic after at least 5 years of follow-up; they were proposed to have smoldering multiple myeloma (SMM). Over time, SMM was defined by arbitrary numerical values (≥10 % plasma cells in the bone marrow and serum M-protein concentration ≥ 3 g/dL). Numerous clinical scores have been developed to define high-risk groups for progression to MM. Current statistical models for progression provide only average risk scores, offering limited clinical utility since the risk of progression at an individual level remains unknown. Physician-scientists are focusing on emerging technologies, such as whole genome sequencing, tumor microenvironment analysis, and single-cell RNA sequencing, to understand precursor states at a molecular level. The overarching goal of these technologies is to better characterize monoclonal gammopathy and other myeloma precursor states. This will enable clinicians to provide more precise, individualized risk assessments and ultimately improve patient outcomes. This review outlines the history of MM precursor states, current definitions, challenges in risk stratification models, and the role of emerging technologies in enhancing predictions and outcomes.
A randomized, double-blind, 12 week parallel dietary intervention study is conducted to evaluate the effects of the two novel food products containing fermented rye bran in normal weight and overweight men and women with prevalent HP infection. A follow-up is planned at week 24. The primary endpoint is severity of HP infection indicated by a breath test. Secondary endpoints include effects on chronic inflammation, insulin resistance, blood lipids, blood cholesterol,body weight, intestinal microbial clusters et al. The food products given to the treatment group will be a novel breakfast cereal product and a crispbread product containing fermented rye bran. The control product will be corresponding products based on refined wheat.
Polymyxin B (PB) and Polymyxin E (PE, also called colistin) are used as the last treatment resort for multidrug-resistant Gram-negative bacterial infections. The nephrotoxicity and neurotoxicity of polymyxins limit their clinical use, and guidelines recommend therapeutic drug monitoring (TDM) to optimize efficacy and reduce toxicity. However, there are limited analytical methods available for the determination of PB and PE. This study aimed to develop a simple and robust liquid chromatography with tandem mass spectrometry (LC-MS/MS) analytical method for determining the main compounds of PB and PE, namely PB1, PB2, ile-PB1, PE1, and PE2, in human plasma and to investigate of their pharmacokinetics in critically ill patients with the use of PB and PE, respectively. Plasma PB1, PB2, ile-PB1, PE1, and PE2 were chromatographically separated on a Welch LP-C18 column and detected using electrospray ionization mode coupled with multiple reaction monitoring. The calibration curve showed acceptable linearity over 20-10,000 ng/mL for PB1, PE1, and PE2 and 10-5000 ng/mL for PB2 and ile-PB1 in the plasma, respectively. After validation following approved guidelines, this method was successfully applied for PB and PE pharmacokinetic analysis and TDM in critically ill patients. Additionally, the composition of PB1, PB2, ile-PB1, PE1, and PE2 remains unchanged from 0 to 12 h after entering the patient's body.
Each Patient will get all four wisdom teeth removed, left and right side separately. After the operation, low level laser therapy is applied intra- and extraorally. Two different lasers are used, one for each side. The two lasers look identical. Only one of the lasers has therapeutic light, the other one shows just non-therapeutic red light. The effect of the low level laser is measured by several parameters and they are compared with the other side. These parameters are pain, swelling and mouth opening. The selection of the lasers to the sides is double-blind and randomized.
Neurodegenerative diseases are characterized by the abnormal filamentous assembly of specific proteins in the central nervous system1. Human genetic studies have established a causal role for protein assembly in neurodegeneration2. However, the underlying molecular mechanisms remain largely unknown, which is limiting progress in developing clinical tools for these diseases. Recent advances in cryo-electron microscopy have enabled the structures of the protein filaments to be determined from the brains of patients1. All neurodegenerative diseases studied to date have been characterized by the self-assembly of proteins in homomeric amyloid filaments, including that of TAR DNA-binding protein 43 (TDP-43) in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) types A and B3,4. Here we used cryo-electron microscopy to determine filament structures from the brains of individuals with FTLD-TDP type C, one of the most common forms of sporadic FTLD-TDP. Unexpectedly, the structures revealed that a second protein, annexin A11 (ANXA11), co-assembles with TDP-43 in heteromeric amyloid filaments. The ordered filament fold is formed by TDP-43 residues G282/G284-N345 and ANXA11 residues L39-Y74 from their respective low-complexity domains. Regions of TDP-43 and ANXA11  that were previously implicated in protein-protein interactions form an extensive hydrophobic interface at the centre of the filament fold. Immunoblots of the filaments revealed that the majority of ANXA11 exists as an approximately 22 kDa N-terminal fragment lacking the annexin core domain. Immunohistochemistry of brain sections showed the colocalization of ANXA11 and TDP-43 in inclusions, redefining the histopathology of FTLD-TDP type C. This work establishes a central role for ANXA11 in FTLD-TDP type C. The unprecedented formation of heteromeric amyloid filaments in the human brain revises our understanding of amyloid assembly and may be of significance for the pathogenesis of neurodegenerative diseases.
The invention relates to a water lily body-tranquillizing and sleep-assisted patch, which is characterized by consisting of a three-layer structure of a high-voltage static electret film backing, an adhesive layer containing medicaments such as water lily leaf, pearl, and salvia miltiorrhiza, and an anti-adhesive protective film. The formula of the patch contains the following effective ingredients: water lily leaf, pearl, salvia miltiorrhiza, spine date seed, Chinese angelica, white peony root, melatonin and a biological cross-linking agent. According to the invention, the patch has the efficacy of tranquillizing the body and settling mind, replenishing qi and settling fright, and nourishing the heart and replenishing the liver depending on synergic interaction of the medicaments such as water lily leaf. Sleep problems are easily solved by simultaneously utilizing four methods of the high-voltage static electret film, melatonin, traditional Chinese medicine formula and acupoint application, which are used for treating internal diseases by external treatment. The water lily body-tranquillizing and sleep-assisted patch has obvious functions of settling fright and tranquillizing the body, can improve the sleep quality, can shorten the sleep latency, and can prolong the sleep time, so that insomnia symptoms caused by various reasons can be removed and relieved. The water lily body-tranquillizing and sleep-assisted patch is especially suitable for people suffering from diseases such as falling-asleep difficulty, dreaminess and unsound sleep, poor sleep quality, chronic insomnia, intractable insomnia, climacteric insomnia, and depressive insomnia.
Patients will be randomized and data interpreters will be blinded to two alternating six-day protocols where the patients will be advised verbally and by written instruction to inject insulin in sites of subclinical lipohypertrophy or normal subcutaneous tissue. Patients will be asked to monitor and record their capillary blood glucose with meals and prior to bedtime using their own capillary blood glucose monitor. A trained research nurse at the Diabetes Centre will instrument each patient with an iPro 2 glucose sensor (Medtronic Canada). These sensors continuously measure blood glucose for periods of up to 7 days. A trained nurse will clean the skin with a superficial disinfectant and a small catheter will be inserted in the subcutaneous tissue at a non-lipohypertrophic site. The catheter will then be attached to a glucose sensor. Patients will wear this sensor for two periods of 6 days each at different sites. At the end of each of the two six day periods, the sensor will be removed.
This pilot study will seek to investigate the use of rituximab in patients with Wegener's granulomatosis who have experienced disease relapse through standard therapies. Rituximab is a chimeric monoclonal antibody directed against CD20, which induces B cell death and results in rapid and sustained depletion of circulating and tissue-based B cells. The objectives of this protocol will be to establish the safety of rituximab in Wegener's granulomatosis, to examine the ability of rituximab to reduce the level of circulating antineutrophil cytoplasmic antibodies (ANCA), and to preliminarily explore whether rituximab is able to prevent disease relapse. This prospective standardized open label trial will enroll 10 patients who have a well-documented history of disease relapse while receiving immunosuppressive therapy given according to published regimens and who are ANCA positive after remission induction. Patients will be enrolled once they have achieved remission from a recent relapse and are receiving either methotrexate or azathioprine for remission maintenance. All patients will receive rituximab 375 mg/M(2) once a week for 4 weeks. During and following the rituximab treatment period, patients will remain on their remission maintenance agent of methotrexate or azathioprine. Patients who are enrolled while on prednisone will continue to taper the dosage to discontinuation as medically permitted. Following the 4 weekly infusions of rituximab, patients will be followed prospectively for evidence of effective B cell depletion, features of drug toxicity, level of circulating ANCA, and clinical disease status. Patients whose ANCA levels become undetectable following the infusion of rituximab may be retreated with a second 4 week course of rituximab should their ANCA titer become positive (greater than or equal to 1:40) and there has been a return of B cells in the peripheral blood. Methotrexate or azathioprine will be continued for two years past remission, after which time, this will be tapered and discontinued. Patients will continue to be monitored for two years off all immunosuppressive therapy or if a disease relapse should occur, for a minimum of 12 months after the last rituximab infusion.
A recombinant human type II mitochondrial dynein-like GTPase gene sequence and application thereof, wherein the nucleotide sequence thereof is represented by SEQ ID NO.: 1. A fusion nucleic acid, comprising a nucleic acid encoding human type II mitochondrial dynein-like GTPase. A recombinant expression vector, comprising the nucleic acid or the fusion nucleic acid. A transformant, which introduces the nucleic acid or the fusion nucleic acid into a host. An ADOA model for a non-human mammal based on type Ⅱ mitochondrial dynein-like GTPase gene inactivation, wherein the recombinant expression vector encoding the human type II mitochondrial dynein-like GTPase can effectively improve pathological manifestations of ADOA. The expression of the nucleic acid encoding the human type II mitochondrial dynein-like GTPase is higher, and therefore, more human type II mitochondrial dynein-like GTPase can be obtained in mitochondria, and eye diseases, such as the ADOA, can be treated better.
Patients will receive conservative therapy - optimal medical treatment (OMT) including statins (at least 10 mg atorvastatin irrespective of the baseline cholesterol level), aspirin (100 mg daily) and antihypertensive therapy (at least 50 mg losartan and 5 mg amlodipine 75 mg daily irrespective of the baseline arterial pressure level). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations.